The ability of thrombin inhibitors to reduce the thrombin activity generated in plasma on extrinsic and intrinsic activation

Thromb Haemost. 1997 Mar;77(3):498-503.

Abstract

In a thrombin generation test with continuous registration of thrombin activity in plasma we studied the ability of a variety of thrombin inhibitors of different type and mechanism of action of influence the activity of thrombin after activation of the coagulation system. Depending on the inhibitor, the peak of thrombin activity is delayed and/or reduced. By blocking the active site of generated thrombin inhibitors cause a concentration dependent reduction of the thrombin peak and inhibit feed-back reactions of thrombin resulting in a delay of thrombin generation. Highly potent synthetic active-site directed inhibitors (Ki < or = 20 nM) reduce the thrombin activity formed in plasma after extrinsic or intrinsic activation with the same efficiency (IC50 0.1-0.6 microM) as hirudin. The delay and reduction of thrombin generation by inhibitors of the anion-binding exosite 1 of thrombin is only attributed to an inhibition of feed-back reactions of thrombin. For a 50% reduction of thrombin activity in plasma by this type of inhibitors relatively high concentrations were determined.

MeSH terms

  • Amino Acid Chloromethyl Ketones / metabolism
  • Amino Acid Chloromethyl Ketones / pharmacology
  • Antithrombins / metabolism
  • Antithrombins / pharmacology*
  • Binding Sites
  • Blood Coagulation / physiology*
  • Blood Coagulation Tests
  • Hirudins / analogs & derivatives
  • Hirudins / metabolism
  • Hirudins / pharmacology
  • Humans
  • Kinetics
  • Peptide Fragments / metabolism
  • Peptide Fragments / pharmacology
  • Recombinant Proteins / metabolism
  • Recombinant Proteins / pharmacology
  • Sulfones / metabolism
  • Sulfones / pharmacology
  • Thrombin / antagonists & inhibitors*
  • Thrombin / metabolism

Substances

  • Amino Acid Chloromethyl Ketones
  • Antithrombins
  • Hirudins
  • Peptide Fragments
  • Recombinant Proteins
  • Sulfones
  • 4-(2-aminoethyl)benzenesulfonylfluoride
  • Thrombin
  • phenylalanyl-prolyl-arginine-chloromethyl ketone
  • bivalirudin